MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS

ABSTRACT

Objective: Recently, we reported that the 218 amino acid murine full-length myelin oligodendrocyte glycoprotein (MOG) contains novel T-cell epitopes p119-132, p181-195, and p186-200, located within its transmembrane and cytoplasmic domains, and that p119-132 is its immunodominant encephalitogenic T-cell epitope in mice. Here, we investigated whether the corresponding human MOG sequences contain T-cell epitopes in patients with multiple sclerosis (MS) and healthy controls (HC).

Methods: Peripheral blood T cells from patients with MS and HC were examined for proliferation to MOG p119-130, p181-195, p186-200, and p35-55 by fluorescence-activated cell sorting analysis using carboxyfluorescein diacetate succinimidyl ester dilution assay. Intracellular production of proinflammatory cytokines was analyzed by flow cytometry.

Results: MOG p119-130, p181-195, and p186-200 elicited significantly greater T-cell responses than p35-55 in patients with MS. T cells from patients with MS proliferated significantly more strongly to MOG p119-130 and p186-200 than did T cells from HC. Further, MOG p119-130-specific T cells exhibited Th17 polarization, suggesting this T-cell epitope may be relevant to MS pathogenesis.

Conclusions: Transmembrane and cytoplasmic MOG domains contain potent T-cell epitopes in MS. Recognition of these determinants is important when evaluating T-cell responses to MOG in MS and may have implications for development of myelin antigen-based therapeutics.

GLOSSARY

Evidence indicates that T cells specific for myelin autoantigens have an important role in the pathogenesis of multiple sclerosis (MS). Although several myelin antigens exist, investigations of T-cell reactivity in MS have focused attention on myelin basic protein (MBP) and proteolipid protein (PLP), which account for approximately 80% of myelin protein, as well as myelin oligodendrocyte glycoprotein (MOG). Although intact MOG protein accounts for only 0.05%–0.1% of total myelin proteins, it was initially reported to induce more potent T-cell responses than other myelin antigens in patients with MS. Subsequent studies in MS have concentrated primarily on T-cell recognition of the 117 amino acid (aa) N-terminal extracellular immunoglobulin (Ig) “variable-like” domain of MOG but have not consistently observed T-cell responses. However, native full-length MOG is 218 aa and contains transmembrane and cytoplasmic domains. In our companion manuscript, we identified 3 T-cell MOG determinants in mice, MOG p119-132, located within the transmembrane region, which induced potent clinical and histologic experimental autoimmune encephalitis (EAE), and MOG p181-195 and p186-200, respectively.
2 discrete T-cell epitopes within the cytoplasmic domain. Upon recall to immunization of mice with full-length MOG, these T-cell epitopes were recognized more frequently than MOG p35-55, indicating they are dominant epitopes. We therefore questioned whether T cells in patients with MS recognize the corresponding peptide sequences of human MOG.

METHODS Patients. Twelve Caucasian patients with MS (66% female, mean age [SD]: 43.2 [12.9] years, mean disease duration [SD]: 5.5 [6.2] years, mean Expanded Disability Status Scale score [SD]: 1.8 [1.0]) and 12 Caucasian healthy controls (HC) (42% female, mean age [SD]: 40.5 [8.8] years) were recruited from the University of California at San Francisco (UCSF) MS Center. Out of 12 patients with MS, 10 had not received disease-modifying therapies prior to the study and 2 were treated with rituximab. Statistical significance between patients with MS and HC occurred regardless of whether the 2 patients treated with rituximab were included in T-cell proliferation and cytokine analysis. None of the patients had received steroids within 2 months preceding blood draws. Blood was collected by venipuncture.

Standard protocol approvals, registrations, and patient consents. This study was approved by the UCSF Committee on Human Research (Protocol 10-00650). Written informed consent was obtained from participants prior to enrollment.

Peptides. Human MOG p119-130 (FYYWSPGVLYLL), MOG p181-195 (TLEFVVIPLGPLVL), and p186-200 (VPVVLGPLVALICYN) were synthesized by Genemed Peptides. Human MOG p119-130 (MEVGWYRPPFSRVHLYRNGK) was purchased from AnaSpec, Inc. (Fremont, CA).

Lymphocyte culture and proliferation assay. Human peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation over Ficoll (Ficoll-Paque PLUS; GE Healthcare, Milwaukee, WI). T-cell proliferation was evaluated as previously described. PBMC were stained with 0.5 μM 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE) (Invitrogen, Carlsbad, CA). After 10 days of culture with antigens, T-cell proliferation was examined by flow cytometric evaluation of CFSE dilution. Proliferation was expressed as the cell division index (defined as the number of CFSE<sup>+</sup> T cells cultured with antigen/number of CFSE<sup>+</sup> T cells without antigen). Culture medium consisted of X-VIVO 15 (Lonza, Walkersville, MD) supplemented with penicillin (100 U/mL) and streptomycin (0.1 mg/mL). Mouse monoclonal anti–HLA-DR (clone G46-6; BD Biosciences), anti–HLA-DQ (clone HG-38; Abcam, Cambridge, MA), anti–HLA-DR but not anti–HLA-DQ or –HLA-DP. These results demonstrated that HLA-DR molecules serve as restriction elements for CD4<sup>+</sup>-specific T cells for production of proinflammatory cytokines. The frequency of Th17 cells and ratio of Th17 to Th1 cells were greater in response to MOG p119-130 and p186-200–specific T cells (figure 2).

Th1 and Th17 cells represent 2 proinflammatory T-cell subsets that may participate in MS pathogenesis. Thus, we examined proliferating MOG peptide-specific T cells for production of proinflammatory cytokines. The frequency of Th17 cells and ratio of Th17 to Th1 cells were greater in response to MOG p119-130 than to the other MOG T-cell determinants examined (figure 2). Further, Th17 p119-130–specific T cells were statistically more frequent in patients with MS than HC. In contrast, the frequency of MOG p186-200–specific Th1 cells appeared to be higher in patients with MS than HC, but it did not reach statistical significance. Collectively, these results clearly demonstrate that the T-cell determinants within the transmembrane and cytoplasmic domains of MOG, shared in mice and humans, are highly stimulatory in patients with MS.

DISCUSSION In 1993, when MOG protein was discovered as a CNS autoantigen, it was reported to induce more potent T-cell responses than MBP, PLP, or myelin-associated glycoprotein (MAG). However,
most subsequent studies utilized peptides corresponding to the extracellular MOG domain (MOG1-125) or recombinant MOG itself and did not consistently observe T-cell reactivity. These findings raised the possibility that T-cell epitopes exist in the other domains. In contrast to many studies that evaluated T-cell proliferation to MOG in MS, we utilized the CFSE dilution assay, which is a sensitive and robust method for measuring T-cell proliferation.
T-cell proliferation. In our study, the 3 transmembrane or cytoplasmic determinants examined elicited stronger T-cell proliferative responses than human MOG p35-55. These observations suggest that MOG p119-130, identified in our accompanying manuscript as an encephalitogenic murine T-cell determinant, may be pathologically relevant in both EAE and MS.

Of interest, a small number of reports that did evaluate T-cell reactivity to peptides corresponding to the intracellular domain of MOG observed similar, or lower, responses in patients with MS than HC. Of note, we observed not only that MOG p119-130 and p186-200 elicited more vigorous T-cell responses than p35-55 but also that these 2 novel T-cell epitopes elicited stronger proliferative responses in patients with MS than HC. In addition, p119-130–specific T cells exhibited significant proinflammatory Th17 polarization. Our demonstration that immunodominant T-cell epitopes exist within the C-terminal 100 residues of intact MOG in mice and that they correspond to determinants in MS should encourage reevaluation of T-cell recognition of MOG in patients with MS.

Two recent studies suggested that MOG-specific IgG antibodies may define a subset of aquaporin-4 (AQP4)-seronegative patients with neuromyelitis optica (NMO). Considered an astrocytopathy, IgG is a T-cell–dependent antibody subclass. While it should be recognized that astroglial histopathology is necessary

Figure 2  T cells from patients with multiple sclerosis (MS) exhibit a proinflammatory bias

CD4+ CFSE™ proliferating T cells (cell division index > 2) were analyzed for interleukin (IL)-17 and interferon (IFN)–γ production by intracellular staining after stimulation with phorbol 12-myristate 13-acetate/ionomycin for 5 hours. Frequencies of IL-17+ IFN–γ, IL-17+ IFN–γ, and IL-17+ IFN–γ were examined among proliferating p119-130–specific CD4+ T cells, p181-195–specific CD4+ T cells, and p186-200–specific CD4+ T cells. Frequencies of IL-17 and IFN–γ single positive T cells were used to calculate Th17/Th1 ratio. Box and whisker plots include the median, distribution, and range. *p < 0.05, Mann–Whitney U test. CFSE = carboxyfluorescein diacetate succinimidyl ester; HC = healthy controls.

T-cell proliferation. In our study, the 3 transmembrane or cytoplasmic determinants examined elicited stronger T-cell proliferative responses than human MOG p35-55. These observations suggest that MOG p119-130, identified in our accompanying manuscript as an encephalitogenic murine T-cell determinant, may be pathologically relevant in both EAE and MS.

Of interest, a small number of reports that did evaluate T-cell reactivity to peptides corresponding to the intracellular domain of MOG observed similar, or lower, responses in patients with MS than HC. Here, we observed not only that MOG p119-130 and p186-200 elicited more vigorous T-cell responses than p35-55 but also that these 2 novel T-cell epitopes elicited stronger proliferative responses in patients with MS than HC. In addition, p119-130–specific T cells exhibited significant proinflammatory Th17 polarization. Our demonstration that immunodominant T-cell epitopes exist within the C-terminal 100 residues of intact MOG in mice and that they correspond to determinants in MS should encourage reevaluation of T-cell recognition of MOG in patients with MS.

Two recent studies suggested that MOG-specific IgG antibodies may define a subset of aquaporin-4 (AQP4)-seronegative patients with neuromyelitis optica (NMO). Considered an astrocytopathy, IgG is a T-cell–dependent antibody subclass. While it should be recognized that astroglial histopathology is necessary

Neurology: Neuroimmunology & Neuroinflammation

© 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
to confirm that this entity indeed represents NMO, it may also be important to evaluate T-cell responses to the immunodominant determinants of MOG in patients with NMO. It is interesting that a murine model containing T cells and B cells that selectively target MOG, a protein expressed on oligodendrocytes and not astrocytes, leads to opticospinal EAE.12 Thus, one can speculate that MOG IgG + AQP4-seronegative NMO could represent a unique form of opticospinal MS.

While myelin antigen-based tolerogenic therapies, including altered peptide ligands, DNA vaccination, intravenous peptide administration, and oral tolerance, have not clearly proven efficacious in phase II and III MS trials, interest in development of therapies that target autoantigen-specific immune cells remains high.13 Of interest, a majority of such studies have tested therapies targeting immune recognition of MBP alone,13 and those investigations that did include MOG concentrated on T-cell epitopes within its extracellular domain.14 Our observations that the transmembrane and cytoplasmic domains of MOG contain highly stimulatory T-cell epitopes in patients with MS underscore the importance of including these domains should myelin antigen-based therapies be further advanced in MS. Further, recognition of including these domains should myelin antigen-based epitopes in patients with MS underscore the importance of MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 2013;210:2921–2928.

REFERENCES

MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS
Michel Varrin-Doyer, Aparna Shetty, Collin M. Spencer, et al.
Neurol Neuroimmunol Neuroinflamm 2014;1;
DOI 10.1212/NXI.0000000000000020

This information is current as of August 14, 2014

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/1/2/e20.full.html

References
This article cites 13 articles, 2 of which you can access for free at:
http://nn.neurology.org/content/1/2/e20.full.html##ref-list-1

Citations
This article has been cited by 2 HighWire-hosted articles:
http://nn.neurology.org/content/1/2/e20.full.html##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Immunology
http://nn.neurology.org/cgi/collection/all_immunology
Autoimmune diseases
http://nn.neurology.org/cgi/collection/autoimmune_diseases
Multiple sclerosis
http://nn.neurology.org/cgi/collection/multiple_sclerosis

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2014 American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.